The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with renal cell carcinoma (RCC).

The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.

To offer optimal care to patients with RCC, clinicians must have a deep understanding of the key trial results and know how to best contextualize evidence to optimize considerations at key decision points along the RCC treatment continuum.

These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced renal cell carcinoma and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.

The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.

The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.

The expansion of treatment options included in the treatment guidelines has certainly improved outcomes of patients with advanced RCC but presents numerous clinical challenges, such as determining best choice of primary treatment for a given patient based on tumor biology and clinical characteristics and in choosing appropriate subsequent lines of treatment.